Late-Breaking Research: Clinical Research 3

• LB320 · PDF Inverse relationship between cancer and Alzheimer's disease: Important interplay between autophagy and apoptosis signaling mechanisms Jagadeesh Narasimhappagari, Meenakshisundaram Balasubramaniam, Srinivas Ayyadevara, W Sue T Griffin
• LB322 · PDF Targeting senescence to reverse chemotherapy-induced muscle aging in breast cancer survivors: An ancillary study of the TROFFi Trial Yuliya Zektser, Catherine Crespi, Sam Margolis, Arman Niknafs, Jingran Ji, Nikita Baclig, Mina Sedrak
• LB324 · PDF The impact of the Community Living Lab learning health system on the prostate cancer knowledge, attitudes, beliefs, and cues to action of Black men Folakemi T. Odedina, Opeyemi Oreoluwa Bolajoko, Quincy A. Wimberly, Daniel W. Lee, Floyd B. Willis, Toshiko Moultrie, Wayne Ford, Derry Green, Arnold J. Merriweather, Michelle Fudge
• LB325 Revising Japan's insurance system and patient advocacy activities Naomi Sakurai, Shinsuke Amano, Hiromi Todoroki, Yoko Matsumoto, Yoshiyuki Majima, Maiko Higuchi, Mina Katome, Ruri Kobayashi, Ayako Yago, Yuka Tsujimoto, Yuri Ito
• LB326 · PDF Point-of-care-manufactured PRAME-specific TCR T cell therapy induces deep remission in a heavily pre-treated pediatric patient with extensive, multifocal nephroblastoma Katharina Mair, Corinne Rossi, Jens H. Westhoff, Esther Wahlbrink, Kendra Maass, Sophia Scheuermann, Fabienne Engelmann, Simon Krost, Alexandra Tuch, Barbara Jones, Laura Fankhauser, Joachim B. Kunz, Johann Greil, Stella Okouoyo, Florian Selt, Elke Pfaff, Jutta Mattern, Maria E. Kögler, Roland Imle, Abdulsattar Alrajab, Jens-Peter Schenk, Inga Harting, Erik Winter, Patrick Günther, Markus Keßler, Astrid Burger, Juri Fuchs, Anita Schmitt, Carsten Müller-Tidow, Kathrin Schramm, Stefanie Volz, Robert J. Autry, David T. W. Jones, Kristian W. Pajtler, Dirk Jäger, Stefan Pfister, Thomas Grünewald, Andreas E. Kulozik, Olaf Witt, Patrick Schmidt, Christian M. Seitz
• LB327 · PDF Optimizing fludarabine exposure in pediatric CAR T-cell patients through an adaptive dosing approach Emma Barlow, Su Han Lum, Geoff Shenton, Denise Bonney, Rachael Hough, Sophie Hambleton, Gareth Veal, Shelby Barnett
• LB328 · PDF Optimising the treatment of childhood cancer patients through adaptive dosing and the generation of evidence-based dosing guidelines Gareth J. Veal, Shelby Barnett, Newcastle Cancer Centre Pharmacology Group
• LB329 · PDF Overcoming the blood-brain barrier to potentiate GD2-CAR T therapy using P-selectin-targeted nanomedicine Giuseppe Longobardi, Adan Miari, Yulia Liubomirski, Ester Buderovsky, Anat Globerson Levin, Ronit Satchi-Fainaro
• LB330 TTFields-TTONIC: Synergizing tumor treating fields with targeted chemotherapy for lung cancer James Villegas, Sunil Prabhu, Jeffrey Wang, Preshita Desai
• LB331 · PDF First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results Yelena Y. Janjigian, Hanneke van Laarhoven, Hirokazu Shoji, Lucjan Wyrwicz, Sara Lonardi, Boguslawa Karaszewska, Xinjun Liang, Aitana Calvo Ferrándiz, Mariusz Kwiatkowski, Keun-Wook Lee, Tianshu Liu, Kohei Shitara, Sun Young Rha, Salvatore Siena, Roy Rabbie, Caron Lloyd, Megan Scott, Arthur W. Lambert, Jeeyun Lee
• LB332 HSK46575, a potent CYP11A1 inhibitor, demonstrates promising monotherapy and synergistic efficacy with SOCs for the treatment of castration-resistant prostate cancer (CRPC) Lulin Huang, Meilin Qian, Ju Wang, Yao Li, Zongjun Shi, Guohua Rong, Pangke Yan
• LB334 · PDF Patient-derived 3D tumor models integrated with AI-driven treatment matching for target discovery and personalized therapy Anshika Katyal, Anne Krinsky, Opal Avramoff, Yulia Liubomirski, Gal Dinstag, Omer Tirosh, Ranit Aharonov, Tuvik Beker, Iris Barshack, Shaked Lev-Ari, Shirly Grynberg, Ronnie Shapira-Frommer, Ronit Satchi-Fainaro
• LB335 · PDF Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition Megan A. Satyadi, Rachel Bridgens, Haley Todd, Grace Goodhart, Syed A. Ahmad, Andrew M. Waters
• LB336 · PDF VRN110755: A next-generation non-covalent EGFR tyrosine kinase inhibitor for EGFR-mutated NSCLC Hong-ryul Jung, Tsung-Ying Yang, Byung-Yong Shim, Chia-Chi Lin, Myung-Ju Ahn, Daekwon Kim
• LB337 · PDF Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC) Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
• LB340 · PDF Mechanism-based trial matching reveals a 54% target alignment gap in ovarian cancer: Quantifying the precision-eligible ovarian cancer patients Fahad Kiani

在完整检索应用中浏览本分会场 →